ABSTRACT
We consider the transmission dynamics of COVID-19 which is characterized by two distinct features. One is the existence of asymptomatic carriers which is the hidden variable in the problem. The other is the issue of latency which means that among the symptomatic carriers there could be a fraction whose symptoms develop after a couple of days. We write down a Henon-like map to take these effects into account and find that the map has an unusual fixed point which corresponds to a very high ratio of asymptomatic to symptomatic infected persons. This fixed point has its own stability zone and influences the dynamics overall. Although a rather elementary model, we show that it is not totally devoid of reality.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No IRB approval was required as our paper is completely mathematical and no clinical test are done.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.